Drug Trial Radar · NCT05392179
A Study in Subjects With Retinitis Pigmentosa
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jul 14, 2022
Primary completion
Jun 23, 2023
Study completion Jun 23, 2023
Sponsor
- Lead sponsor
- Aldeyra Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.
Conditions
- Retinitis Pigmentosa
Interventions
ADX-2191Drug
Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of three injections. Evaluation through week 16.
ADX-2191Drug
Monthly intravitreal injections of ADX-2191 (400 µg in 0.05 mL) for a total of six injections. Evaluation through week 16.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Serious Adverse EventsTime frame: The safety assessment period was 16 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Duke Eye Center
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.